Generic-drug-makers retool as patent cliff wanes

Opportunities are drying up for makers of generic drugs as the value of treatments set to lose patent protection and be sold as generics is anticipated to drop by more than half in 2013 to around $17 billion, a Crédit Agricole Securities analysis found. Many makers of generics are trying to adapt through acquisitions, branded products or treatments that are hard to produce.

View Full Article in:

New York Times (tiered subscription model), The